Article

Stone recurrence: Advice for young urologists

In this video, Juan Calle, MD, of Cleveland Clinic, explains what he would tell a young urologist who wants to become an expert in stone prevention and minimizing recurrence.

Juan Calle, MD, of Cleveland Clinic, explains what he would tell a young urologist who wants to become an expert in stone prevention and minimizing recurrence.

Related Videos
Raevti Bole, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Petar Bajic, MD, answers a question during a video interview
Raevti Bole, MD, answers a question during a video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Related Content
FDA grants de novo clearance to Stone Clear device
November 13th 2024

FDA grants de novo clearance to Stone Clear device

Hannah Clarke
"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1
September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke
YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
Increasing thiazide doses linked to fewer kidney stone events
August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke
“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.
Trial launches of gene editing therapy for primary hyperoxaluria type 1
August 24th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1

Hannah Clarke
In total, the trial plans to enroll 7 patients with PH1 through a single center in China.
© 2024 MJH Life Sciences

All rights reserved.